Esketamine is approved in Europe for treating resistant major depressive disorder-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Esketamine is approved in Europe for treating resistant major depressive disorder

Published:2019-12-20 Issue: Volume: Page:l7069
ISSN:1756-1833
Container-title:BMJ
language:en
Short-container-title:BMJ

Author:

Mahase Elisabeth

Publisher

BMJ

Subject

General Engineering

Reference3 articles.

1. Spravato (esketamine) nasal spray approved in Europe for adults with treatment resistant major depressive disorder. December 2019. www.businesswire.com/news/home/20191219005272/en/SPRAVATO%C2%AE%E2%96%BC-Esketamine-Nasal-Spray-Approved-Europe-Adults.

2. SpravatoEMA. 2019. www.ema.europa.eu/en/medicines/human/EPAR/spravato.

3. Esketamine for treatment resistant depression

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of antidepressant treatment on blood BDNF levels in depressed patients: A review and methodological recommendations for assessment of BDNF in blood;European Neuropsychopharmacology;2024-10

2. Potent and reversible open-channel blocker of NMDA receptor derived from dizocilpine with enhanced membrane-to-channel inhibition;Biomedicine & Pharmacotherapy;2024-09

3. Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review;European Neuropsychopharmacology;2024-09

4. Fast-acting antidepressant-like effects of ketamine in aged male rats;Pharmacological Reports;2024-08-19

5. Combined Effects of Nasal Ketamine and Trauma-Focused Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder: A Pilot Case Series;Behavioral Sciences;2024-08-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP